Vai al contenuto principale
Coronavirus: aggiornamenti per la comunità universitaria / Coronavirus: updates for UniTo Community

Translational Hematology

Prof.ssa Marta Coscia (Principal Investigator)

  translationalhematology1.jpg

Activities

The research activity of the laboratory of Translational Hematology is focused on:

  • The evaluation of immune dysfunctions occurring in patients with lymphoproliferative diseases, with a special interest in patients with chronic lymphocytic leukemia (CLL)
  • The impact of conventional and novel targeted therapies on the immune system of patients with lymphoproliferative diseases and CLL
  • The study of intrinsic, microenvironment-related or immune-mediated mechanisms favouring tumor progression and inducing resistance to apoptosis and to drug-induced cell death in CLL cells.
  • Development of novel strategies of adoptive immunotherapy, with the aim of improving anti-tumor efficacy and reducing side effects in lymphoproliferative diseases

Group:

  • Research Funding from Janssen Research & Development, LLC: "Immunomodulatory effects of single-agent ibrutinib treatment in chronic lymphocytic leukemia patients", Ruolo: Principal Investigator (2016 – presente).
  • Research Funding from Karyopharm Therapeutics Inc., a Delaware corporation: "In vitro evaluation of the activity of Selinexor (KPT-330) in combination with antineoplastic agents against chronic lymphocytic leukemia primary cells", Ruolo: Principal Investigator (2014 – presente).
  • Sponsored Phase I/III clinical trials investigating the efficacy of innovative treatments in chronic lymphocytic leukemia. Role: Principal Investigator (2014 - presente).
  • AIRC19653 Fellowship: “Exploring the regulation of HIF-1α and its potential for therapeutic intervention in chronic lymphocytic leukemia”.
  • AIRC16343 Fellowship: “Understanding the CXCL12/CXCR4 axis and mevalonate pathway cross-talk to overcome fludarabine resistance in CLL”.
  • Active participation to the research and clinical projects of ERIC, GIMEMA gruppo linfoproliferative croniche.

 

 

Ultimo aggiornamento: 08/04/2022 12:23